New drug trial targets Tough-to-Treat head and neck cancers

NCT ID NCT06857279

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called HLX43 in people with advanced head and neck cancer that has returned or spread. The goal is to find a safe and effective dose and see if the drug can shrink tumors and help patients live longer. About 167 participants will receive the drug through an IV at different dose levels to compare results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA OF HEAD AND/OR NECK are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
RECRUITING

Jinan, Shandong, 250117, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CARCINOMA OF HEAD AND/OR NECK